Date Added: 20/03/2017

Date Updated: 20/03/2017

DNX-2401 for recurrent glioblastoma – in combination with pembrolizumab

Specialties: Oncology & radiotherapy

Technology Type: Drugs

Stage of development: Experimental - pilot or phase II

Stage of EAA: Prioritised for assessment

Description, patients and keywords:


Glioblastoma or gliosarcoma tumour: recurrent; where gross total resection is not possible or advisable – second line; in combination with pembrolizumab.


DNX-2401 (adenovirus-5 delta 24 RGD; ad-delta24-RGD; Ad-DNX 2401; IE-CRAd; RGD-delta24; VLI-01A) uses a genetically modified adenovirus genome to replicate selectively in retinoblastoma-pathway (Rb) deficient cells. DNX-2401 triggers tumour cell necrosis and intratumoural immune cell infiltration. Replicated copies of DNX-2401, tumour antigens and immune factors are released on cell lysis, stimulating continued tumour response.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.